<DOC>
	<DOCNO>NCT02632201</DOCNO>
	<brief_summary>Objectives : The purpose study evaluate safety efficacy PIK-HER2 cell treatment advance Her2 high express gastric cancer liver metastasis patient . Methods : This study design novel therapy use PIK-HER2 cell . 40 Her2 positive patient liver metastasis gastric cancer enrol . They randomly divide dendritic cell-precision multiple antigen T cell ( DC-PMAT ) group PIK-HER2 cell group . Both DC-PMAT treatment PIK-HER2 cell treatment perform every 3 week total three period . The mail clinical indicator Progression-Free-Survival Overall Survival .</brief_summary>
	<brief_title>Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 ( PIK-HER2 ) Cells Treatment Advanced Gastric Cancer With Liver Metastasis</brief_title>
	<detailed_description>A total 40 patient may enrol period 1-2 year .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Age 18~65 year old , male female 2 . Life expectancy ＞ 6 month 3 . Eastern Cooperative Oncology Group ( ECOG ) score : 02 4 . The stomach gastroesophageal junction carcinoma hepatic metastasis 5 . Adenocarcinoma 6 . The expression HER2 immunohistochemical tumor tissue great equal 2 level 7 . Creatinine le 2.5mg/dL ; alanine aminotransferase ( ALT ) / aspartate aminotransferase ( AST ) T le 3 time normal ; bilirubin le 3mg/dL 8 . Blood routine conforms requirement blood sample 9 . Signed informed consent 10 . Patients fertility willing use contraceptive method . 1 . Expected Overall survival ＜ 6 month 2 . Other serious disease : heart , lung , kidney , digestive , nervous , mental disorder , immune regulatory disease , metabolic disease , infectious disease , Etc . 3 . Serum creatinine &gt; 2.5mg/dL ; Serum Glutamic Oxaloacetic Transaminase ( SGOT ) &gt; 5 time normal ; total bilirubin &gt; 100μmol/L 4 . Without sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>PIK-HER2 cell</keyword>
	<keyword>dendritic cell-precision multiple antigen T cell</keyword>
</DOC>